{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:22:07Z","timestamp":1791372127099,"version":"4.3.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although paclitaxel plus bevacizumab (PB) therapy is an effective chemotherapeutic regimen for HER2-negative advanced breast cancer (ABC), predictive markers for its effectiveness remain undefined. We investigated the usefulness of systemic immunity markers associated with lymphocytes as predictive markers for PB therapy in patients with HER2-negative ABC. We retrospectively reviewed data from 114 patients with HER2-negative ABC who underwent PB therapy from November 2011 to December 2019. We calculated the absolute lymphocyte count (ALC), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) as representative systemic immunity markers. The time to treatment failure (TTF) and overall survival (OS) of the patients with high ALC, low NLR, and high LMR were significantly longer compared with those of the patients with low ALC, high NLR, and low LMR. A multivariable analysis revealed that high ALC, low NLR, and low PLR were independent predictors for TTF and high ALC, low NLR, and high LMR were independent predictors for OS. Systemic immunity markers were significantly associated with longer TTF and OS in patients who underwent PB therapy and may represent predictive markers for PB therapy in patients with HER2-negative ABC.<\/jats:p>","DOI":"10.1038\/s41598-021-85948-2","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T16:47:41Z","timestamp":1616086061000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8043-8608","authenticated-orcid":false,"given":"Shogo","family":"Nakamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsumasa","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akifumi","family":"Notsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,18]]},"reference":[{"key":"85948_CR1","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller, K. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666\u20132676. https:\/\/doi.org\/10.1056\/NEJMoa072113 (2007).","journal-title":"N. Engl. J. Med."},{"key":"85948_CR2","doi-asserted-by":"publisher","first-page":"4966","DOI":"10.1200\/JCO.2008.21.6630","volume":"27","author":"R Gray","year":"2009","unstructured":"Gray, R., Bhattacharya, S., Bowden, C., Miller, K. & Comis, R. L. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J. Clin. Oncol. 27, 4966\u20134972. https:\/\/doi.org\/10.1200\/JCO.2008.21.6630 (2009).","journal-title":"J. Clin. Oncol."},{"key":"85948_CR3","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ejca.2016.09.024","volume":"70","author":"D Miles","year":"2017","unstructured":"Miles, D. et al. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): a double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. Eur. J. Cancer 70, 146\u2013155. https:\/\/doi.org\/10.1016\/j.ejca.2016.09.024 (2017).","journal-title":"Eur. J. Cancer"},{"key":"85948_CR4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ejca.2017.10.018","volume":"90","author":"D Miles","year":"2018","unstructured":"Miles, D., Cameron, D., Hilton, M., Garcia, J. & O\u2019Shaughnessy, J. Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer. Eur. J. Cancer 90, 153\u2013155. https:\/\/doi.org\/10.1016\/j.ejca.2017.10.018 (2018).","journal-title":"Eur. J. Cancer"},{"key":"85948_CR5","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1093\/annonc\/mdw260","volume":"27","author":"S Delaloge","year":"2016","unstructured":"Delaloge, S. et al. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study. Ann. Oncol. 27, 1725\u20131732. https:\/\/doi.org\/10.1093\/annonc\/mdw260 (2016).","journal-title":"Ann. Oncol."},{"key":"85948_CR6","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.21873\/invivo.11917","volume":"34","author":"S Nakamoto","year":"2020","unstructured":"Nakamoto, S., Watanabe, J., Ohtani, S., Morita, S. & Ikeda, M. Bevacizumab as first-line treatment for HER2-negative advanced breast cancer: paclitaxel plus bevacizumab versus other chemotherapy. In Vivo 34, 1377\u20131386. https:\/\/doi.org\/10.21873\/invivo.11917 (2020).","journal-title":"In Vivo"},{"key":"85948_CR7","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/bjc.2013.69","volume":"108","author":"DW Miles","year":"2013","unstructured":"Miles, D. W. et al. Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br. J. Cancer 108, 1052\u20131060. https:\/\/doi.org\/10.1038\/bjc.2013.69 (2013).","journal-title":"Br. J. Cancer"},{"key":"85948_CR8","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013 (2011).","journal-title":"Cell"},{"key":"85948_CR9","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.critrevonc.2013.03.010","volume":"88","author":"GJ Guthrie","year":"2013","unstructured":"Guthrie, G. J. et al. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit. Rev. Oncol. Hematol. 88, 218\u2013230. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.03.010 (2013).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"85948_CR10","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/jnci\/dju124","volume":"106","author":"AJ Templeton","year":"2014","unstructured":"Templeton, A. J. et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J. Natl. Cancer Inst. 106, 124. https:\/\/doi.org\/10.1093\/jnci\/dju124 (2014).","journal-title":"J. Natl. Cancer Inst."},{"key":"85948_CR11","doi-asserted-by":"publisher","first-page":"5383","DOI":"10.1158\/0008-5472.CAN-08-3845","volume":"69","author":"I Ray-Coquard","year":"2009","unstructured":"Ray-Coquard, I. et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 69, 5383\u20135391. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-3845 (2009).","journal-title":"Cancer Res."},{"key":"85948_CR12","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1158\/1055-9965.EPI-14-0146","volume":"23","author":"AJ Templeton","year":"2014","unstructured":"Templeton, A. J. et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol. Biomark. Prev. 23, 1204\u20131212. https:\/\/doi.org\/10.1158\/1055-9965.EPI-14-0146 (2014).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"85948_CR13","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.ctrv.2015.10.003","volume":"41","author":"TF Nishijima","year":"2015","unstructured":"Nishijima, T. F., Muss, H. B., Shachar, S. S., Tamura, K. & Takamatsu, Y. Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: a systematic review and meta-analysis. Cancer Treat. Rev. 41, 971\u2013978. https:\/\/doi.org\/10.1016\/j.ctrv.2015.10.003 (2015).","journal-title":"Cancer Treat. Rev."},{"key":"85948_CR14","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.breast.2011.11.002","volume":"21","author":"MA Vicente Conesa","year":"2012","unstructured":"Vicente Conesa, M. A. et al. Predictive value of peripheral blood lymphocyte count in breast cancer patients treated with primary chemotherapy. Breast 21, 468\u2013474. https:\/\/doi.org\/10.1016\/j.breast.2011.11.002 (2012).","journal-title":"Breast"},{"key":"85948_CR15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13058-016-0794-1","volume":"19","author":"JL Ethier","year":"2017","unstructured":"Ethier, J. L., Desautels, D., Templeton, A., Shah, P. S. & Amir, E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res. 19, 2. https:\/\/doi.org\/10.1186\/s13058-016-0794-1 (2017).","journal-title":"Breast Cancer Res."},{"key":"85948_CR16","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.18632\/oncotarget.13714","volume":"8","author":"Y Zhu","year":"2017","unstructured":"Zhu, Y. et al. Platelet-lymphocyte ratio acts as an indicator of poor prognosis in patients with breast cancer. Oncotarget 8, 1023\u20131030. https:\/\/doi.org\/10.18632\/oncotarget.13714 (2017).","journal-title":"Oncotarget"},{"key":"85948_CR17","doi-asserted-by":"publisher","first-page":"e111886","DOI":"10.1371\/journal.pone.0111886","volume":"9","author":"XJ Ni","year":"2014","unstructured":"Ni, X. J. et al. An elevated peripheral blood lymphocyte-to-monocyte ratio predicts favorable response and prognosis in locally advanced breast cancer following neoadjuvant chemotherapy. PLoS ONE 9, e111886. https:\/\/doi.org\/10.1371\/journal.pone.0111886 (2014).","journal-title":"PLoS ONE"},{"key":"85948_CR18","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.clbc.2018.03.002","volume":"18","author":"Y Miyagawa","year":"2018","unstructured":"Miyagawa, Y. et al. Significant association between low baseline neutrophil-to-lymphocyte ratio and improved progression-free survival of patients with locally advanced or metastatic breast cancer treated with eribulin but not with nab-paclitaxel. Clin. Breast Cancer 18, 400\u2013409. https:\/\/doi.org\/10.1016\/j.clbc.2018.03.002 (2018).","journal-title":"Clin. Breast Cancer"},{"key":"85948_CR19","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10549-020-05626-1","volume":"181","author":"J Watanabe","year":"2020","unstructured":"Watanabe, J., Saito, M., Horimoto, Y. & Nakamoto, S. A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience. Breast Cancer Res. Treat. 181, 211\u2013220. https:\/\/doi.org\/10.1007\/s10549-020-05626-1 (2020).","journal-title":"Breast Cancer Res. Treat."},{"key":"85948_CR20","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s12282-020-01067-2","volume":"27","author":"Y Miyoshi","year":"2020","unstructured":"Miyoshi, Y. et al. High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician\u2019s choice-in the EMBRACE study. Breast Cancer 27, 706\u2013715. https:\/\/doi.org\/10.1007\/s12282-020-01067-2 (2020).","journal-title":"Breast Cancer"},{"key":"85948_CR21","doi-asserted-by":"publisher","first-page":"469","DOI":"10.4161\/cbt.24425","volume":"14","author":"C Botta","year":"2013","unstructured":"Botta, C. et al. Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. Cancer Biol. Ther. 14, 469\u2013475. https:\/\/doi.org\/10.4161\/cbt.24425 (2013).","journal-title":"Cancer Biol. Ther."},{"key":"85948_CR22","doi-asserted-by":"publisher","first-page":"33210","DOI":"10.18632\/oncotarget.8901","volume":"7","author":"A Passardi","year":"2016","unstructured":"Passardi, A. et al. Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer. Oncotarget 7, 33210\u201333219. https:\/\/doi.org\/10.18632\/oncotarget.8901 (2016).","journal-title":"Oncotarget"},{"key":"85948_CR23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.18632\/oncotarget.27423","volume":"11","author":"Y Miyagawa","year":"2020","unstructured":"Miyagawa, Y. et al. Baseline neutrophil-to-lymphocyte ratio and c-reactive protein predict efficacy of treatment with bevacizumab plus paclitaxel for locally advanced or metastatic breast cancer. Oncotarget 11, 86\u201398. https:\/\/doi.org\/10.18632\/oncotarget.27423 (2020).","journal-title":"Oncotarget"},{"key":"85948_CR24","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3389\/fonc.2015.00202","volume":"5","author":"PA Ott","year":"2015","unstructured":"Ott, P. A., Hodi, F. S. & Buchbinder, E. I. Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data. Front. Oncol. 5, 202. https:\/\/doi.org\/10.3389\/fonc.2015.00202 (2015).","journal-title":"Front. Oncol."},{"key":"85948_CR25","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1158\/2326-6066.CIR-14-0053","volume":"2","author":"FS Hodi","year":"2014","unstructured":"Hodi, F. S. et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol. Res. 2, 632\u2013642. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0053 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"85948_CR26","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski, M. A. et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378, 2288\u20132301. https:\/\/doi.org\/10.1056\/NEJMoa1716948 (2018).","journal-title":"N. Engl. J. Med."},{"key":"85948_CR27","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/jco.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff, A. C. et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline update. J. Clin. Oncol. 31, 3997\u20134013. https:\/\/doi.org\/10.1200\/jco.2013.50.9984 (2013).","journal-title":"J. Clin. Oncol."},{"key":"85948_CR28","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda, Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transpl. 48, 452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244 (2013).","journal-title":"Bone Marrow Transpl."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85948-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85948-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85948-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T05:33:23Z","timestamp":1670045603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85948-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,18]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["85948"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-85948-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,18]]},"assertion":[{"value":"24 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Nakamoto reports having received personal fees from Chugai Pharmaceuticals, Eisai, and Taiho Pharmaceuticals outside of the submitted work; Dr. Ikeda reports having received personal fees from AstraZeneca, Chugai Pharmaceuticals, Daiichi-Sankyo, Eisai, Eli-Lilly, Kyowa Kirin, Pfizer, Nippon Kayaku, Novartis, Mundipharma, Celltrion Healthcare, and Sawai Pharmaceuticals outside of the submitted work; Dr. Kubo has received lecture fees from Eli-Lilly outside of the submitted work; Dr. Yamamoto has received lecture fees from Bayer outside of the submitted work. The other authors have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6328"}}